Objective: To investigate the effect of Oxcarbazepine in the treatment of epilepsy and its effect on serum inflammatory factor, intercellular adhesion molecule 1 (ICAM-1) and immune function.Methods:A total of 95 patients with epilepsy were selected as observation group, another 95 cases of healthy people as control group;The patients in the observation group were given oral treatment of Oxcarbazepine Tablets, for 6 months;Detection of the observation group before and after treatment of serum inflammatory cytokines (IL-2, IL-6, TNF-α) level, ICAM-1 index and immune function of peripheral T lymphocyte subsets of CD3+, CD4+, CD8+ and immunoglobulin (IgG, IgA, IgM) level, and compared with the normal control group.Results:Before treatment, The observation group of patients with levels of IL-2, IL-6, TNF-α, ICAM-1, CD8+, IgA and IgG were significantly higher than those in control group (P<0.05), compared with the control group, CD3+,CD4+ levels were significantly decreased (P<0.05);The level of IgM in the observation group was higher than that in the control group, but the difference between the two groups was not significant (P>0.05);Compared with the group before treatment, IL-2, IL-6, TNF-alpha, ICAM-1, CD8+, IgA and IgG levels in the observation group after treatment were significantly lower, however, compared with the control group, the levels of above indexes were still increase significantly (P<0.05);After treatment the levels of CD3+, CD4+ of the observation group were significantly increased, but the levels were still significantly lower than the control group, the difference was statistically significant (P<0.05);There was no significant change in IgM levels after treatment (P>0.05).Conclusions: Patients with epilepsy exist abnormal levels of inflammatory factorsand ICAM-1, immune dysfunction, oxcarbazepine in the treatment of epilepsy patients can effectively reduce the inflammatory factor and the level of ICAM-1, plays a positive role in regulating immune function disorder.%目的:探讨奥卡西平药物治疗对癫痫患者血清炎性因子、细胞间粘附分子1(ICAM-1)及免疫功能的影响.方法:选取确诊为癫痫患者95例作为观察组,另选取95例健康体检人群作为对照组;观察组患者给予口服奥卡西平片治疗,连续治疗6个月;检测观察组治疗前后血清炎性因子(IL-2、IL-6、TNF-α)水平、ICAM-1及免疫功能相关指标:外周T淋巴细胞亚群CD3+、CD4+、CD8+及免疫球蛋白(IgG、IgA、IgM)水平变化,并与正常对照组进行比较分析.结果:治疗前,观察组的IL-2、IL-6、TNF-α、ICAM-1、CD8+、IgA和IgG水平均显著高于对照组(P<0.05);CD3+、CD4+水平较对照组显著降低(P<0.05);IgM水平较对照组升高,但差异无统计学意义(P>0.05);与组内治疗前相比,观察组的IL-2、IL-6、TNF-α、ICAM-1、CD8+、IgA和IgG水平均显著降低,但各指标水平均显著高于对照组,差异有统计学意义(P<0.05);观察组治疗后的CD3+、CD4+水平显著升高,但两者水平仍显著低于对照组,差异有统计学意义(P<0.05);治疗后IgM水平较治疗前及对照组比较,差异无统计学意义(P>0.05).结论:癫痫患者存在炎性因子及ICAM-1水平异常和免疫功能的紊乱,奥卡西平治疗可有效降低癫痫患者的炎性因子及ICAM-1水平,对免疫功能紊乱的调节具有积极的作用.
展开▼
